PAG
ACAD icon

Private Advisor Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Private Advisor Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-150
Closed -$7K – 1565
2020
Q2 		$7K Buy
+150
New +$7.2K ﹤0.01% 3056

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Private Advisor Group's ACAD Position: Q3 2020 in Review

Private Advisor Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 150 shares — an estimated $7K sold.

Private Advisor Group first reported a position in ACAD in Q2 2020 and held it in 1 quarter. The position peaked at $7K in Q2 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Private Advisor Group reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 150 Acadia Pharmaceuticals shares in Q3 2020, an estimated $7K.
  • Private Advisor Group first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Acadia Pharmaceuticals position peaked at $7K in Q2 2020.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.